Role of the Interaction Between Advanced Glycation End Products and Their Receptor RAGE in the Development and the Progression of the Uremic Vasculopathy of Hemodialyzed Patients

Not Applicable

Completed

• Conditions: Hemodialyzed Patients
• Interventions: Other: Vascular calcifications by Xray; Other: Vascular calcifications by tomodentimetry; Biological: Blood sample withdrawn

• Registration Number: NCT02818465
• Lead Sponsor: CHU de Reims

Brief Summary

Chronic kidney disease (CKD) is associated with an extensive vasculopathy and high cardiovascular mortality as well as an accumulation of uremic toxins. Among the latest, advanced glycation end-products (AGEs) interact with RAGE. Investigators aimed to analyze the role of RAGE in the calcification process of hemodialyzed patients, in a correlative and prospective study. Vascular calcifications will be assessed by Xray and tomodentimetry while accumulation of AGEs will be measured in the serum and in the skin (non invasive). Additionally factors influencing RAGE activation such as genetic polymorphism and level of soluble forms of RAGE will be measured and analyzed.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-03-30
• Study First Submitted: 2016-06-23
• Study First Submitted QC: 2016-06-27
• Study First Posted: 2016-06-29
• Primary Completion: 2017-11-16
• Study Completion: 2017-11-16
• Status Verified: 2018-04
• Last Update Submitted: 2018-04-18
• Last Update Posted: 2018-04-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Renal impairment
• Hemodialysis for more than 3 months
• Have agreed to participate in research
• Affiliated to a social security scheme
• major

Exclusion Criteria

• Diabetes , for diabetes induces accelerated formation of advanced glycation end products , which could then be a confounding factor in our study.
• Protected by law .
• minors
• pregnant women
• Matt or pigmented skin because the skin hyperpigmentation interfere with reading the skin fluorescence giving falsely elevated values .
• Having an aneurysm of the abdominal aorta known
• Suffering from a progressive neoplastic disease

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Patients	Blood sample withdrawn	-
Patients	Vascular calcifications by tomodentimetry	-
Patients	Vascular calcifications by Xray	-

Primary Outcome Measures

Name	Time	Method
Frammingham Score	up to 12 months

Trial Locations

Locations (1)

Chu de Reims; 🇫🇷 Reims, France